What’s Under The Iceberg: GE Healthcare’s Deep Dive Look At Future Of Gene Therapy
What’s Under The Iceberg: GE Healthcare’s Deep Dive Look At Future Of Gene Therapy
$200.00
As gene therapy becomes an increasingly prominent area of interest, players are formulating new strategies to enter the marketplace. In Vivo speaks with GE Healthcare’s General Manager of Cell and Gene Therapy for an inside look at the company’s plans to expand into this area.
Author: William Looney
Publisher: InVivo
- Description
Phil Vanek, PhD, GE Healthcare’s General Manager of Cell and Gene Therapy and Alliance for Regenerative Medicine (ARM) board member, sat down with In Vivo to discuss the company’s future plans and strategy for gene and cell therapy expansion. Tap into his views of the essential steps biopharma companies hoping to succeed in this area must undertake, from properly ad proactively addressing logistical issues, to effectively managing capital assets, to tips for attracting top talent, in this illuminating interview.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Poseida, Legend/Janssen Look To Snag Celgene/ Bluebird’s BCMA Crown 
Sign up to the